Bringing New Therapies to Market

 Today’s post was written by Bert E. Thomas IV, PhD, MBA, CEO of the Sarcoma Foundation of America.   Over the past few weeks we’ve seen the Food and Drug Administration (FDA) make decisions regarding some investigational therapies for sarcoma.  In that time, one investigational new drug received priority review status, which cuts the drug review period from 10 months to six months.  Another was given fast track designation.  This designation is also intended to expedited the review process for “serious conditions with unmet medical need.”  Certainly sarcoma falls into that category. The Sarcoma Foundation of America (SFA) has long been…  Read More »